Author:
Li Changchang,Xue Heng,Du Xinjing,Nyaruaba Raphael,Yang Hang,Wei Hongping
Abstract
Abstract
Background
The outer membrane vesicles (OMVs) produced by Gram-negative bacteria can modulate the immune system and have great potentials for bacterial vaccine development.
Results
A highly active Acinetobacter baumannii phage lysin, LysP53, can stimulate the production of OMVs after interacting with A. baumannii, Escherichia coli, and Salmonella. The OMVs prepared by the lysin (LOMVs) from A. baumannii showed better homogeneity, higher protein yield, lower endotoxin content, and lower cytotoxicity compared to the naturally produced OMVs (nOMVs). The LOMVs contain a significantly higher number of cytoplasmic and cytoplasmic membrane proteins but a smaller number of periplasmic and extracellular proteins compared to nOMVs. Intramuscular immunization with either LOMVs or nOMVs three times provided robust protection against A. baumannii infections in both pneumonia and bacteremia mouse models. Intranasal immunization offered good protection in the pneumonia model but weaker protection (20–40%) in the bacteremia model. However, with a single immunization, LOMVs demonstrated better protection than the nOMVs in the pneumonia mouse model.
Conclusions
The novel lysin approach provides a superior choice compared to current methods for OMV production, especially for vaccine development.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13:605–19.
2. Sartorio MG, Pardue EJ, Feldman MF, Haurat MF. Bacterial outer membrane vesicles: from discovery to applications. Annu Rev Microbiol. 2021;75:609–30.
3. Balhuizen MD, Veldhuizen EJA, Haagsman HP. Outer membrane vesicle induction and isolation for vaccine development. Front Microbiol. 2021;12:629090.
4. Fang W, Jing Z, Li Y, Zhang Z, Lin Z, Yang Z, Tian Y, Zhang C, Ma Y, Hou L, et al. Harnessing enucleated cancer cells as trojan horse cell vaccines. Cell Rep Phys Sci. 2024;5:101752.
5. Lin Z, Meng F, Ma Y, Zhang C, Zhang Z, Yang Z, Li Y, Hou L, Xu Y, Liang X, Zhang X. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity. Bioact Mater. 2024;32:12–27.